L-Carnitine Market to Reach USD 262.6 Million with a CAGR of 4.8% Till 2027

Posted by Arianna Huffington on December 22nd, 2022

According to The Insight Partners latest study on “The global L Carnitine Market to 2027 – Analysis and Forecast by Process (Chemical Synthesis, Bio-process); Product (Food, Pharmaceutical Grade, Feed Grade); Application (Animal Feed, Healthcare Products, Functional Drinks, Medicines), and Geography”. L-Carnitine is a naturally occurring compound in the bodies of humans and animals which playsan  important role of shuttling fatty acids to and fro in the cells to produce energy. It is produced in the liver and kidneys. However, certain individuals are unable to produce or synthesize required amount of L-Carnitine owing to genetic conditions or defects. Individuals unable to synthesize L-Carnitine suffer from primary and secondary carnitine deficiency. The US Food and Drug Administration (FDA) has approved the use of oral and intravenous (IV) L-Carnitine for treating primary and secondary carnitine deficiency. At present, L-Carnitine is commercially advertised as nutritional supplements to enhance exercise performance and promote weight loss. It is also approved to be used in the treatment of carnitine deficiencies in patients at the end stage of renal diseases undergoing hemodialysis. Besides its uses in human nutrition, L-Carnitine is also used as an additive in the formulation of animal feed formulations. It is used in the poultry industry to increase egg production and improve egg hatchability.

The global L Carnitine market was valued at US$ 172.2 Mn in 2018 and is projected to reach US$ 262.6 Mnby 2027; it is expected to grow at a CAGR of 4.8% during 2019–2027. The report includes key understanding on the driving factors of this growth and also highlights the prominent players in the market and their developments.

ALPSURE LIFESCIENCES PVT. LTD, Biosint S.p.A., Cayman Chemical, Cheng Da PharmaCeuticals Co., Ltd, Huang Gang Hua Yang Pharmaceutical Co., Ltd, Kaiyuan Hengtai Nutrition Co., Ltd., Lonza Group Ltd, Maxsun Industries Incorporated, Merck KGaA, and Northeast Pharmaceutical Group Co., Ltd, are among the key players present in the global L Carnitine market.

Based on process, the L-carnitine market has been segmented into chemical synthesis and bio-process. The market for bio-process is expected to grow at a higher CAGR during the forecast period. Bioprocess is a method employed in the production of L-Carnitine owing to its highest yield and the environmental benefits that it offers. An upsurge in demand for commercial product compels manufacturers to improve their production process to increase the yield. Biological processes making use of microorganisms and enzymes are inherently asymmetric processes.

The most commonly used bioprocess that generates highest yield is based on the biotransformation of achiral precursors like 3- dehydrocarnitine, crotonobetaine and y-butyrobetaine or racemic mixtures such as D, L-carnitine, D, L-acyl carnitine and D, L –carnitinamide. Both, D-carnitine and crotonobetaine can be used as a biotransformation substrate for the production of l-carnitine. Increased productivity of L-Carnitine is also achieved by using a genetically modified strain overproducing the multifunctional protein CaiD that forms a part of both carnitine dehydrate (CDH) and carnitine racemase (CRac) activities. However, compared to the classical chemical method of racemate synthesis involving resolution of the enantiomers, the use of fed-batch cultivation of rhizobium like a strain for the enantioselective production of the racemate, involves 50% less of total organic waste, 25% less of water and 90% less water for incineration.

L-Carnitine has been recommended by medical professionals globally to individuals with genetic disorders whose bodies are unable to naturally synthesize carnitine. L-Carnitine plays a major role in keeping up with the requirements of energy production in the body, as it is involved in transporting long-chain fatty acids to the mitochondria for energy production. The US Food and Drug Administration has approved the use of (IV) L-Carnitine for treating primary and secondary carnitine deficiencies. L-Carnitine supplements are also used to treat carnitine deficiencies resulting from poor carnitine absorption and chronic kidney failure. Moreover, the widespread use of carnitine in treating carnitine deficiency in end-stage renal diseases resulting from dialysis has compounded the consumption of L-Carnitine in the form of supplements. The use of L-Carnitine in the form of supplements to cure involuntary weight loss and increase the body mass index (BMI) in patients with cachexia or wasting syndrome has steadily risen. Rising consumption of L-Carnitine to improve lean body mass in people with wasting syndrome is expected to further boost the growth of the L-Carnitine market. The L Carnitine market in APAC is expected to grow at the highest CAGR during the forecast period.Factors such as growing demand for nutritional supplements coupled with increasing use in the personal and sports nutrition product are driving its demand in APAC. Functional food and beverages have gained immense popularity among the health-conscious population that has made an impact on the demand for L carnitine in the region.

Read More: https://www.theinsightpartners.com/reports/l-carnitine-market